Table 2.
Antibodies to tau currently in clinical development.
| Antibody | Epitope location | Immunization strategy | Binding Selectivity | Ab species and backbone isotype | Current Status (2019–2020) | Company | Clinical outcomes |
||
|---|---|---|---|---|---|---|---|---|---|
| Last completed Trial (Disease,Phase) | Patient stage | Reduced tau burden | |||||||
| Gosuranemab, BIIB092, BMS-986168, IPN007/IPN002) | 15–24 | In vitro aggregated full-length tau | M, NFT?, eTaua | humanized IgG4 | NCT03352557 (AD,II) | iPerian/Bristol-Meyers Squibb/Biogen | NCT02460094 (PSP,I), NCT03068468 (PSP,II,dd) | MCI/Mild AD | + |
| ABBV-8E12 (C2N-8E12, HJ8.5) | 25–30 (within 22–34) | recombinant full-length tau | M, NFT, eTau | humanized IgG4 | NCT03712787 (AD,II), NCT02880956(AD,II) | C2N Diagnostics/Abbvie | NCT02494024 (PSP,I) NCT03391765 (PSP,I,d) | Early AD | + |
| Zagotenemab (LY3303560, MC-1 IgG1) | 7–9/312–322 (discontiguous) | Immunopurified PHFs | M-,O,NFT | humanized IgG4 | NCT03518073 (AD,II) | Eli Lilly | NCT02754830, NCT03019536 (AD,I) | healthy, mild to moderate AD | –c |
| Semorinemab (RO7105705, MTAU9937A, RG6100) | 2–24 (C-terminal portion) | recombinant oligomers | M,NFT,eTau | humanized IgG4 | NCT03828747 (AD,II), NCT03289143 (AD,II) | AC Immune, Genentech, Hoffmann-La Roche | NCT02820896 (AD,I) | Mild to moderate AD | + |
| BIIB076 (NI-105.6C5 huIgG1λ) | probably 125−131 | N/A: B-cells from healthy subjects | M, PFF, NFT | human IgG1 | NCT03056729 (AD,I) | Biogen/Neurimmune | NCT03056729 (AD,I) | Healthy/MCI AD | +b |
| RG7345 (RO6926496) | 416–430 (pS422) | 416–430 (pS422) peptide | phospho M, PHF | humanized IgG1 or IgG4 | NCT02281786 (I,d) | Hoffmann-La Roche | NCT02281786 (I,d) | healthy males | − |
| UCB0107 (D IgG4) | 235–246 | Recombinant tau fibrils | M,O,PHF | humanized IgG4 or IgG1 | NCT03464227 (AD,I), NCT03605082 (AD,I) NCT04185415 (PSP,I,s) | UCB Biopharma | NCT03464227 (I), NCT03605082 (I) | Healthy males, healthy m/f | − |
| JNJ-63733657 (B296, PT3) | 204–225 (pT212/pT217) | PHF from AD patients | M,PHF (ptau) | humanized, likely IgG1 | NCT03375697 (prodromal, mild AD,I) | Janssen | NCT03689153 (I) | healthy m/f | + |
| NPT088 | --c | N/A: Human IgG -viral g3p GAIM chimera | O,F/P | Human IgG1 | NCT03008161 (I) | Proclara Biosciences | NCT03008161 (I) | Mild to moderate AD | − |
a
M = Monomers, O=Oligomers, NFT = Neurofibrillary tangles, eTau = extracellular tau, PFF = pre-formed fibrils, PHF = paired-helical filaments.
b
in cynomolgus monkeys.
c
indicates “not reported”.
d
d = Discontinued.